A targeted drug that hits the wrong target — in the kidney
BRAF/MEK-inhibitor tubular injury
Vemurafenib was built to block a mutated melanoma kinase, but in the kidney its damage is off-target: it injures the proximal tubule and can produce a Fanconi picture, usually early and usually mild — and, paradoxically, pairing it with a MEK inhibitor makes it gentler on the kidney, not harsher.
- 24%
- develop AKI on BRAF+MEKShare of 38 BRAF-mutated melanoma patients on vemurafenib plus cobimetinib who developed AKI (creatinine ≥1.5× baseline) in a single-center cohort
- <3 months
- onset windowAll 9 AKI cases in that cohort were diagnosed within the first trimester of treatment — an early, monitorable signal rather than a late one
- 77%
- were mild (stage 1)Most AKI episodes were CTCAE stage 1; the remaining 23% were stage 2 — the tubular injury is usually mild and improves with dose modification
- 60%
- less AKI with MEK addedAdding the MEK inhibitor cobimetinib to vemurafenib reduced AKI incidence by 60% versus vemurafenib monotherapy in the same center's experience
- off-target
- not a BRAF effectIn cell and mouse models, vemurafenib tubular toxicity was BRAF-independent — tubular BRAF deletion did not change it; off-target inhibition of ferrochelatase (a heme-synthesis enzyme) drove the injury
Teaching case · illustrative composite, not a real patient
A 58-year-old woman with BRAF V600E-mutated metastatic melanoma is six weeks into vemurafenib plus cobimetinib when routine labs show her creatinine risen from 0.8 to 1.4 mg/dL. She is not volume-depleted; the urine is bland but shows glycosuria with a normal glucose, low-grade proteinuria, and a serum phosphate of 2.1 mg/dL with mild metabolic acidosis.
The early creatinine rise with glycosuria (normoglycemic), phosphate wasting, and a bland sediment points to a proximal tubular injury — a partial Fanconi picture — rather than prerenal or obstructive AKI. Prerenal and obstructive causes are excluded and other nephrotoxins are reviewed. Because the injury is mild (CTCAE stage 1), the BRAF inhibitor is dose-reduced with close monitoring; electrolytes are repleted. Renal function and the tubular losses recover over the following weeks, and full-dose therapy is cautiously resumed. Had this been dabrafenib rather than vemurafenib, a later, steroid-responsive granulomatous interstitial nephritis would have been the pattern to watch for instead.
Teaching point — BRAF-inhibitor nephrotoxicity — vemurafenib above all — is a proximal tubular injury that can present as Fanconi syndrome (glycosuria, phosphaturia, bicarbonate and low-molecular-weight protein wasting), and its mechanism is off-target: it is BRAF-independent and traces to ferrochelatase inhibition, not the intended kinase. It appears early (usually within the first three months) and is usually mild and reversible with dose modification, so the move is baseline-and-monthly creatinine plus a tubular work-up when it rises. Counterintuitively, the BRAF+MEK doublet causes less AKI than BRAF monotherapy. Dabrafenib's renal signature differs — a rarer, later granulomatous interstitial nephritis that responds to steroids.
How it happens
The pathophysiology as a cascade — select a step to follow the mechanism.
How we learned it
- 2014
Launay-Vacher et al. publish the first case series of vemurafenib-associated acute renal failure — 8 patients, some with severe injury and persistent kidney disease — in a drug whose original safety profile listed no renal signal.
First recognition that the melanoma cornerstone vemurafenib can injure the kidney, prompting routine renal monitoring.
PMID 24737576 - 2015
Denis et al. report vemurafenib-induced Fanconi syndrome, localizing the injury to the proximal tubule.
Defined the tubular phenotype — a Fanconi picture — that distinguishes BRAF-inhibitor nephrotoxicity from prerenal or glomerular injury.
PMID 25494458 - 2017
Teuma et al. follow 38 patients on vemurafenib plus cobimetinib: 24% developed AKI, all within the first trimester and mostly mild, and adding the MEK inhibitor cut AKI incidence by 60% versus vemurafenib alone.
Quantified the incidence, timing, and severity — and showed the combination is gentler on the kidney than BRAF monotherapy.
PMID 28396940 - 2021
Bai et al. show in cell and mouse models that vemurafenib kidney toxicity is BRAF-independent — tubular BRAF deletion doesn't change it — and is driven instead by off-target inhibition of ferrochelatase.
Reframed the injury as an off-target effect, explaining why it is a drug-specific tubular toxicity rather than a class-wide on-target one.
PMID 34534550 - 2022
Krelle et al. report biopsy-proven granulomatous interstitial nephritis on dabrafenib plus trametinib — a late (5-year) AKI that resolved with corticosteroids and drug cessation.
Documented dabrafenib's distinct renal signature — an interstitial, steroid-responsive nephritis rather than vemurafenib's early tubular injury.
PMID 34350734
The landmark studies
Adjunction of a MEK inhibitor to vemurafenib results in a 60% reduction of acute kidney injury
Teuma C, et al. · Cancer Chemother Pharmacol 2017 · PMID 28396940
AKI was common but early and usually mild on vemurafenib plus cobimetinib, and the MEK-inhibitor combination reduced nephrotoxicity relative to vemurafenib monotherapy.
AKI 9/38 (24%), all in the first trimester; 77% stage 1, 23% stage 2; baseline eGFR 105 (AKI+) vs 80 mL/min (AKI−), p=0.009; AKI down 60% vs monotherapy
Kidney toxicity of the BRAF-kinase inhibitor vemurafenib is driven by off-target ferrochelatase inhibition
Bai Y, et al. · Kidney Int 2021 · PMID 34534550
Vemurafenib injures tubular epithelial cells independently of BRAF; the off-target inhibition of ferrochelatase, a heme-biosynthesis enzyme, sensitizes tubular cells to death.
Tubular BRAF deletion did not alter toxicity; ferrochelatase overexpression protected and knockdown sensitized cells; 2 weeks of vemurafenib caused moderate AKI in mice
Acute renal failure associated with the new BRAF inhibitor vemurafenib: a case series of 8 patients
Launay-Vacher V, et al. · Cancer 2014 · PMID 24737576
Vemurafenib can cause significant to severe acute renal failure, including renal sequelae and persistent kidney disease in some patients — the first description of the signal.
8 patients with significant-to-severe ARF; renal sequelae/persistent CKD in a subset; no renal signal in the original safety profile
Acute granulomatous interstitial nephritis on dabrafenib and trametinib — a case report
Krelle A, et al. · Cancer Rep 2022 · PMID 34350734
Dabrafenib plus trametinib caused a late, biopsy-confirmed granulomatous interstitial nephritis that improved with corticosteroids and drug cessation — a different lesion from vemurafenib's tubular injury.
Onset ~5 years in; creatinine 80→174 µmol/L, eGFR >90→42 mL/min; granulomatous AIN on biopsy; treated with prednisolone 1 mg/kg
What the data says now
AKI on vemurafenib + cobimetinib
Single-center cohort of 38 BRAF-mutated melanoma patients
PMID 28396940AKI reduction with MEK inhibitor added
Combination vs vemurafenib monotherapy, same center
PMID 28396940First vemurafenib ARF case series
Patients with significant-to-severe ARF, some with persistent CKD
PMID 24737576How it's managed
- 1
Monitor creatinine at baseline and monthly
Because the AKI appears early (within the first three months) and is usually asymptomatic, check serum creatinine before starting a BRAF inhibitor and monthly on treatment so the tubular injury is caught while it is still mild.
First case series — renal monitoring recommended after the signal emerged · PMID 24737576
- 2
Work up the proximal tubule when creatinine rises
A creatinine rise with glycosuria (normoglycemic), phosphate and bicarbonate wasting, or low-molecular-weight proteinuria points to proximal tubular injury / Fanconi rather than prerenal or obstructive AKI — check electrolytes and a urinalysis and replete losses.
Fanconi-syndrome report defining the tubular phenotype · PMID 25494458
- 3
Dose-modify — it is usually reversible
Most cases are CTCAE stage 1 and improve with dose reduction or brief interruption, with full recovery common; persistent CKD occurs in a minority, so re-check renal function and the tubular indices after any dose change before resuming full dose.
Cohort — 77% stage 1, early onset, generally reversible · PMID 28396940
- 4
For dabrafenib AIN, think steroids
Dabrafenib's renal signature is a rarer, later granulomatous interstitial nephritis; when biopsy confirms it, corticosteroids plus stopping the drug improve renal function — a different playbook from vemurafenib's tubular injury.
Biopsy-proven case — prednisolone 1 mg/kg with recovery · PMID 34350734
What the guidelines say
Society and consensus recommendations addressing this syndrome, each with its key recommendation quoted verbatim.
Every citation on this page is a real, PubMed-verified reference. The teaching case is an illustrative composite, not a real patient. Medical-education content — not medical advice.